- Open Access
Hepatocellular adenoma: comparison between real-time contrast-enhanced ultrasound and dynamic computed tomography
SpringerPlus volume 5, Article number: 951 (2016)
To investigate and compare the contrast-enhanced ultrasound (CEUS) features of histologically proven HCA with those of contrast-enhanced computed tomography (CECT).
Eighteen patients with proven hepatic adenoma by pathology were retrospectively selected from the CEUS database. Fourteen of them had undergone liver CECT exams. The basic features on unenhanced imaging and the enhancement level and specific features on contrast-enhanced imaging were retrospectively analyzed, and the differences between CEUS and CECT were compared.
All the HCAs showed hyper-enhancement in the arterial phase. During the portal and late phases, 12 HCAs (12/18, 66.7 %) on CEUS and 11 (11/14, 78.6 %) on CT showed washout. On CEUS, 10 (10/18, 55.5 %) showed centripetal filling in the arterial phase and persistent peripheral rim enhancement. Five of them (61.1 %, 11/18) showed delayed central washout in the portal or late phase. However, on CECT, 2 (14.3 %, 2/14) and 4 (28.6 %, 4/14) HCAs showed persistent enhancement of the peripheral rim and central non-enhancing hemorrhage areas, respectively.
Compared with dynamic CT, CEUS was superior at characterizing specific dynamic features. Considering that it is radiation-free, readily availability and easy to use, CEUS is suggested as the first line imaging tool to diagnose HCA.
Hepatic adenoma (HCA) is the third most common benign hepatic neoplasm. It may undergo malignant transformation and has a marked tendency to hemorrhage (Laumonier et al. 2008). The differential diagnosis with other focal liver lesions (FLLs), particularly focal nodular hyperplasia (FNH) and well-differentiated hepatocellular carcinoma (HCC), is of great significance because of the different management and outcomes for patients (Bartolozzi et al. 1997; Dietrich et al. 2005; Kim et al. 2008; Roche et al. 2015; Kong et al. 2015; Lizardi-Cervera et al. 2006). Therefore, a non-invasive diagnosis is beneficial for further treatment.
Because of its broad availability and a faster multi-row detector, computed tomography (CT) has become an excellent tool for the detection and characterization of FLLs. Typical enhancements of HCA on CT are likely to be iso-attenuated with the surrounding liver on unenhanced CT, becoming hyper-attenuated in the arterial phase and then fading to iso-/hypo-attenuation in the portal or late phase (Hussain et al. 2006; Ichikawa et al. 2000). Hemorrhage and calcification in HCA are present at low sensitivities of 9–15.7 and 5–15 %, respectively (Hussain et al. 2006; Ichikawa et al. 2000). However, these imaging features are not specific to the diagnosis of HCA (Ronot and Vilgrain 2014). Furthermore, considering the radiation hazard, characterization of HCA using CT is a questionable practice.
Contrast-enhanced ultrasound (CEUS) has provided a real-time technique to delineate lesions (Bartolotta et al. 2009). It is believed that CEUS can depict more morphologic features of FLLs owing to its high spatial and temporal resolution (Wang et al. 2013; Claudon et al. 2013). On CEUS, in addition to centripetal enhancement in the arterial phase, persistent peripheral rim enhancement and delayed central washout are also reported as specific dynamic features for the characterization of HCA (Kong et al. 2015; Roche et al. 2015). Because CEUS is radiation-free, readily available and easy to use, many centers have employed CEUS as a routine part of their work-up of FLLs (Jung et al. 2007).
To date, many studies have focused on the differential diagnosis of HCA and FNH using CEUS (Dietrich et al. 2005; Kim et al. 2008; Kong et al. 2015). However, few studies have compared the characteristics of HCA on CEUS with those on dynamic CT. The purpose of our study was to compare the CEUS features of histologically proven HCA with those of CT.
This retrospective study was approved by the ethics committee of the first and third hospital of Sun Yat-Sen University, and informed consent was obtained from all subjects. From June 2008 to October 2015, 18 patients (9 men and 9 women; mean age ± SD, 33 years ± 8; age range 18–52 years) were histologically proven to have hepatic adenoma and were retrospectively selected from our database. The pathological diagnosis was obtained by specimens from ultrasound-guided percutaneous biopsy (n = 2) or surgical resection (n = 16). Fourteen patients had undergone a dynamic CT of the liver. Their basic characteristics are presented in Table 1.
All examinations were performed using the Aplio XV or 500 (Toshiba Medical Systems, Tokyo, Japan), equipped with a 375BT convex transducer (frequency range of 1.9–6.0 MHz), or the MyLab Twice (Esaote Medical Systems, Genoa, Italy), equipped with a CA541 convex transducer (frequency range of 1.0–8.0 MHz). The contrast-specific imaging modes used in the present study were contrast harmonic imaging (MI, 0.06–0.08) and contrast tuned imaging (MI, 0.06–0.10). After activation of the contrast mode, 2.4 ml of SonoVue (Bracco, Milan, Italy) were administered intravenously in a bolus fashion and flushed by 5 ml of 0.9 % saline solution. The target lesion was observed continuously for 6 min, and the entire arterial, portal and late phases were stored on the hard disk. The arterial, portal and late phases were defined as 0–30, 31–120 and 121–360 s after injection, respectively. All the CEUS examinations were performed by two experienced radiologists (W.W. and X.Y.X), both of whom had more than 8 years of experience in liver CEUS.
Among 18 HCAs, 14 were analyzed with CT (Aquilion 64, Toshiba Medical System, Tokyo, Japan) within 2 weeks before or after the CEUS examination. The standard dynamic contrast-enhanced scan procedure is as follows: After an unenhanced helical sequence scan through the liver, 80–100 ml (1.5 ml/kg) of a contrast agent (Ultravist 300, Schering, Berlin, Germany) were administered via the antecubital vein at a rate of 3–4 ml/s. The following CT acquisition parameters were used: 120 kV; 200–250 mAs; collimation: 64 mm × 0.5 mm; slice thickness: 0.5 mm; slice increments: 0.5 mm; and pitch: 0.9. The arterial, portal and late phases were defined as 0–45, 46–120 and 121–360 s after injection, respectively.
CEUS and dynamic CT images were retrospectively analyzed in consensus by two investigators (Z.W. and L.D.C.), both of whom had more than 6 years of experience evaluating liver imaging. They were not involved in the US or CT scanning and were unaware of the clinical and imaging information of the patients. The enhancement level of each phase and specific enhancement pattern were evaluated. The level of enhancement was subdivided into hypo-enhancement, iso-enhancement, and hyper-enhancement compared with the surrounding liver parenchyma. Centripetal filling was defined as rapid centripetal progression of the enhancement in the arterial phase. Persistent peripheral rim enhancement was defined as persistent hyper-echogenicity at the rim of the lesion in the arterial, portal and late phases. Central washout was defined as hypo-enhancement in the center of the lesion compared with the peripheral region (Claudon et al. 2013).
The statistical analysis was performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). Data were presented as the mean ± standard deviation (SD). P < 0.05 was considered to indicate statistical significance. The detection rate of imaging features between CEUS and dynamic CT was assessed using χ2 or Fisher’s exact test.
Basic features on unenhanced imaging
There were 6 (6/18, 33.3 %); 9 (9/18, 50.0 %); and 3 (3/18, 16.7 %) lesions located in the left, right and both lobes of the liver, respectively. The mean size of the lesions was 8.4 ± 5.5 cm (range 1.4–20 cm). All lesions were round shaped with clear boundary. On gray scale ultrasonography, 9 of 18 lesions (9/18, 50.0 %) appeared hypoechoic to the background liver parenchyma, and 6 (6/18, 33.3 %); 2 (2/18, 11.1 %); and 1 (1/18, 5.6 %) lesions appeared hyperechoic, isoechoic and mixechoic, respectively. On color Doppler, a short, rod-like flow pattern in HCAs or periphery vessels of the lesions was detected (8/18, 44.4 %). On the CT scan, 12 of 14 lesions (85.7 %) appeared hypo-attenuated to the background liver parenchyma, and only 1 lesion (1/8, 12.5 %) appeared hyper-, iso- and mix-attenuated, respectively (Table 1).
Enhancement level in vascular phases
On CEUS (n = 18) and dynamic CT (n = 14), all HCAs showed hyper-enhancement in the arterial phase. During the portal phase, 7 (7/18, 38.9 %) and 3 (8/14, 57.1 %) HCA showed hypo-enhancement on CEUS and dynamic CT, respectively. The washout continued on both imaging modalities in the late phase, with 12 HCAs (12/18, 66.7 %) on CEUS and 11 (11/14, 78.6 %) on CT showing hypo-enhancement. On both CEUS and dynamic CT, there were five enhancement patterns: “hyper-hypo-hypo”; “hyper-iso-hypo”; “hyper-iso-iso”; “hyper-hyper-hyper”; and “hyper-hyper-hypo” (Fig. 1, Table 2). No statistical significance was found among enhancement types on CEUS and dynamic CT (all P > 0.05).
Specific features on contrast-enhanced imaging
For the 18 HCAs with real-time CEUS, ten (10/18, 55.6 %) showed centripetal filling in the arterial phase (Fig. 2), and 11 (61.1 %, 11/18) showed persistent peripheral rim enhancement in the arterial, portal and late phases. Five (5/18, 27.8 %) showed delayed central washout in the portal or late phase. Three (3/18, 16.7 %) HCAs showed a central non-enhancing area that indicated a possible hemorrhage (Fig. 3). On CECT, 4 HCAs (4/14, 28.6 %) showed a central non-enhancing hemorrhage area. Specific features were more frequently detected on CEUS than on dynamic CT (all P < 0.05), except for central non-enhancement (P = 0.351) (Table 2). The vascular characteristics of the inflammatory HCAs and HNF-1 alpha mutated HCAs were summarized in Table 3.
It has been reported that HCAs are most common in women who have taken oral contraceptives for long periods of time (Baum et al. 1973). The male-to-female ratio is 1:9, which is lower than that in our study (1:1). Our data coincide with reports from Asia (Kong et al. 2015; Hung et al. 2001) that suggested that a lower use of oral contraceptives in women and routine screening for hepatocellular carcinoma in men may result in a different male-to-female incidence ratio.
Several imaging modalities have been employed in the diagnosis of hepatic adenoma. However, no specific characteristics of HCAs can be identified on unenhanced imaging. Most HCAs are hypo-echoic or hyper-echoic on US and hypo-attenuated to the background liver parenchyma on CT. The mean size of HCAs in our study is larger than in previous reports (Zhu et al. 2011; Ricci et al. 2008). Although larger lesions are at a higher risk of hemorrhage, the echogenicity in our study were homogeneous. Unlike the spoke-wheel flow pattern of FNH, short rod-like or periphery vessels on color Doppler cannot proved effective diagnostic information for HCA (Kong et al. 2015).
On enhanced imaging, most reports showed that 45–60 % of HCAs were hyper-vascular in the arterial phase and hypo-enhanced in the portal or late phase. In our study, almost 70 % of lesions exhibited this enhancement pattern on CEUS and CECT, which can be encountered in HCC and hyper-enhancing metastases. Moreover, HCA with inhomogeneous enhancement is very difficult to discriminate from HCC in a non-cirrhosis liver. In case of this, future developments, such as elastography or new perfusion imaging, might be useful for classification of benign and malignant lesions (Wiggermann et al. 2013; Jung et al. 2007). On the other hand, 30.0 % of lesions on CEUS and 37.5 % on CECT appear to have sustained enhancement in later phases. Although this enhancement pattern suggests a benign tumor, a difficult differential diagnosis with FNH can also be encountered (Kong et al. 2015; Roche et al. 2015; Di Carlo et al. 2010; Kim et al. 2008; Dietrich et al. 2005; Bartolozzi et al. 1997).
This diagnostic dilemma could be resolved by specifically characterizing the dynamic imaging features. According to previous studies, HCAs have some special enhancement features, such as centripetal filling and persistent peripheral rim enhancement (Kim et al. 2008; Mathieu et al. 1986). The specific centripetal filling sign, which was discovered on arteriography, was first reported on CEUS by Kim (Kim et al. 2008). This is the main differential feature with FNH, which is characterized by centrifugal filling and central scarring. The detection rate ranges from 20 to 94 % (Laumonier et al. 2012; Kim et al. 2008; Kong et al. 2015), which is consistent with the rate of 55.5 % in our study. Laumonier reported that the inflammatory subtype of HCA had a peripheral rim of sustained enhancement with a hypo-echoic central area (Laumonier et al. 2012). In our study, this persistent peripheral rim enhancement feature was detected in 61.1 % of all HCAs and 50.0 % of inflammatory subtype on CEUS. The detection rate of this specific sign is lower in our cases because of the nine cases with unidentified subtype. However, none of the specific enhancement features discussed above was reported on CT. In our opinion, CEUS with inherent real-time scanning merit is better for display of those features. Although steatosis, calcification, necrosis and intro-tumor vessels on CT were reported in previous studies, these characteristics are not very sensitive (Burns and Wilson 2007; Hussain et al. 2006).
Our study has some limitations. First, it was a retrospective study based on small number of 18 cases, and only 14 of those were evaluated with CT. Second, as we focused on comparisons with CT, the problem of differential diagnosis with FNH or HCC was neglected. Therefore, limited information had been provided for the diagnostic accuracy of CEUS for this issue. Moreover, some imaging features vary depending on the subtype of HCA and/or tumor size. In our study, we failed to describe the correlation between imaging patterns and subtypes because of limited cases.
In conclusion, our study demonstrated that the enhancement level in three vascular phases of HCA on CEUS was consistent with that on CECT. Compared with CECT, the real-time capability of CEUS is superior for characterizing dynamic centripetal filling, peripheral rim of persistent enhancement, and delayed central washout. In addition, because it is radiation-free, readily availability, and easy to use, CEUS has been suggested as the first line imaging tool to diagnose HCA. Further studies using larger sample sizes and comparisons with MRI are required.
Bartolotta TV, Taibbi A, Midiri M, Lagalla R (2009) Focal liver lesions: contrast-enhanced ultrasound. Abdom Imaging 34(2):193–209. doi:10.1007/s00261-008-9378-6
Bartolozzi C, Lencioni R, Paolicchi A, Moretti M, Armillotta N, Pinto F (1997) Differentiation of hepatocellular adenoma and focal nodular hyperplasia of the liver: comparison of power Doppler imaging and conventional color Doppler sonography. Eur Radiol 7(9):1410–1415
Baum JK, Bookstein JJ, Holtz F, Klein EW (1973) Possible association between benign hepatomas and oral contraceptives. Lancet 2(7835):926–929
Burns PN, Wilson SR (2007) Focal liver masses: enhancement patterns on contrast-enhanced images–concordance of US scans with CT scans and MR images. Radiology 242(1):162–174. doi:10.1148/radiol.2421051006
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX (2013) Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012: a WFUMB–EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 34(1):11–29. doi:10.1055/s-0032-1325499
Di Carlo I, Pulvirenti E, Toro A, Priolo GD (2010) Adenoma or atypical hepatic focal nodular hyperplasia: role of preoperative imaging and laparoscopic treatment. Surg Laparosc Endosc Percutaneous Tech 20(3):E105–E109. doi:10.1097/SLE.0b013e3181e0b2e6
Dietrich CF, Schuessler G, Trojan J, Fellbaum C, Ignee A (2005) Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 78(932):704–707. doi:10.1259/bjr/88181612
Hung CH, Changchien CS, Lu SN, Eng HL, Wang JH, Lee CM, Hsu CC, Tung HD (2001) Sonographic features of hepatic adenomas with pathologic correlation. Abdom Imaging 26(5):500–506
Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper JW, den Hollander J (2006) Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. Eur Radiol 16(9):1873–1886. doi:10.1007/s00330-006-0292-4
Ichikawa T, Federle MP, Grazioli L, Nalesnik M (2000) Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 214(3):861–868. doi:10.1148/radiology.214.3.r00mr28861
Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F (2007) Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol 13(47):6356–6364
Kim TK, Jang HJ, Burns PN, Murphy-Lavallee J, Wilson SR (2008) Focal nodular hyperplasia and hepatic adenoma: differentiation with low-mechanical-index contrast-enhanced sonography. Am J Roentgenol 190(1):58–66. doi:10.2214/ajr.07.2493
Kong WT, Wang WP, Huang BJ, Ding H, Mao F, Si Q (2015) Contrast-enhanced ultrasound in combination with color Doppler ultrasound can improve the diagnostic performance of focal nodular hyperplasia and hepatocellular adenoma. Ultrasound Med Biol 41(4):944–951. doi:10.1016/j.ultrasmedbio.2014.11.012
Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H (2008) Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 48(3):808–818. doi:10.1002/hep.22417
Laumonier H, Cailliez H, Balabaud C, Possenti L, Zucman-Rossi J, Bioulac-Sage P, Trillaud H (2012) Role of contrast-enhanced sonography in differentiation of subtypes of hepatocellular adenoma: correlation with MRI findings. AJR Am J Roentgenol 199(2):341–348. doi:10.2214/AJR.11.7046
Lizardi-Cervera J, Cuellar-Gamboa L, Motola-Kuba D (2006) Focal nodular hyperplasia and hepatic adenoma: a review. Ann Hepatol 5(3):206–211
Mathieu D, Bruneton JN, Drouillard J, Pointreau CC, Vasile N (1986) Hepatic adenomas and focal nodular hyperplasia: dynamic CT study. Radiology 160(1):53–58. doi:10.1148/radiology.160.1.3520655
Ricci P, Cantisani V, D’Onofrio M, Sahani D, Pagliara E, Calliada F, Mehmet E, Sanjeva K, Faccioli N, Pozzi-Mucelli R, D’Ambrosio U, Passariello R (2008) Behavior of hepatocellular adenoma on real-time low-mechanical index contrast-enhanced ultrasonography with a second-generation contrast agent. J Ultrasound Med 27(12):1719–1726
Roche V, Pigneur F, Tselikas L, Roux M, Baranes L, Djabbari M, Costentin C, Calderaro J, Laurent A, Rahmouni A, Luciani A (2015) Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): effect of size on diagnostic confidence. Eur Radiol 25(1):186–195. doi:10.1007/s00330-014-3363-y
Ronot M, Vilgrain V (2014) Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol 38(6):681–688. doi:10.1016/j.clinre.2014.01.014
Wang W, Chen LD, Lu MD, Liu GJ, Shen SL, Xu ZF, Xie XY, Wang Y, Zhou LY (2013) Contrast-enhanced ultrasound features of histologically proven focal nodular hyperplasia: diagnostic performance compared with contrast-enhanced CT. Eur Radiol 23(9):2546–2554. doi:10.1007/s00330-013-2849-3
Wiggermann P, Brunn K, Rennert J, Loss M, Wobser H, Schreyer AG, Stroszczynski C, Jung EM (2013) Monitoring during hepatic radiofrequency ablation (RFA): comparison of real-time ultrasound elastography (RTE) and contrast-enhanced ultrasound (CEUS): first clinical results of 25 patients. Ultraschall Med 34(6):590–594. doi:10.1055/s-0033-1355820
Zhu XL, Chen P, Guo H, Zhang N, Hou WJ, Li XY, Xu Y (2011) Contrast-enhanced ultrasound for the diagnosis of hepatic adenoma. J Int Med Res 39(3):920–928
LDC, WW and MDL designed the research; FLY, ZY, JYL, YH, HLG and XYX performed the research; ZW, EJX and HLG analyzed the data; FLY and WW wrote the paper. All authors read and approved the final manuscript.
Li-Da Chen is the primary corresponding author, and Zhu Wang is the secondary corresponding author. Our work is supported by the National Nature Science Foundation of China (No. 81301238). We appreciate YiLong Education, Inc, for advices of statistical analysis.
The authors declare that they have no competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Wei Wang and Jin-Ya Liu contributed equally to this work
About this article
Cite this article
Wang, W., Liu, JY., Yang, Z. et al. Hepatocellular adenoma: comparison between real-time contrast-enhanced ultrasound and dynamic computed tomography. SpringerPlus 5, 951 (2016). https://doi.org/10.1186/s40064-016-2406-z
- Hepatocellular adenoma
- Contrast-enhanced ultrasound
- Dynamic computed tomography